But being closely in touch with my Inner Asshole, I have to admit a smile will flash briefly across my psyche when this kind of news presents itself.
“Proud boy” leading member, Aaron Laigaie, died from Covid
Aaron Laigaie, one of the founders of the Proud Boys and a Covid denier and anti vaxxer has died of Covid.
Aaron Laigaie, one of the founders of the Proud Boys and a Covid denier and anti vaxxer has died of Covid.
According to a post that was published online by Geoff Guenther, Aaron Laigaie has unfortunately passed away. Coronavirus was the cause of death for Aaron Laigaie. According to the reports, Aaron Laigaie was a Trumpzi who asserted that he had “natural resistance” to COVID.
He was infected with COVID. Aaron was a COVID denier all the way through. The SARS-CoV-2 virus is the infectious agent that causes the disease known as coronavirus disease (COVID-19).
According to Google, the majority of people who become ill with COVID-19 will have symptoms that range from mild to moderate and will recover without the need for any special therapy. On the other hand, some of them will become gravely ill and call for medical assistance.
Aaron Laigaie’s refusal to get the COVID19 shot has come to light thanks to a number of people on social media. He was one of the original members of the MT Baker Proud Boys. The Proud Boys are an all-male, neo-fascist, far-right organization with its headquarters in the United States. They are known for their participation in political violence and for encouraging others to do the same. It has also been called a street gang, although the governments of Canada and New Zealand have classified it as a terrorist organization.
The Proud Boys are a well-known organization that criticizes left-wing and progressive groups and is well-known for its backing of former US President Donald Trump. Another Trumpzi who claimed to be “naturally immune” (from brains, I should guess) has passed away with COVID, Geoff Guenther said on Facebook. Aaron Laigaie, a proud boy, is no longer with us.
A review and meta-regression of 26 studies shows that hybrid SARS-CoV-2 immunity provides the highest level of protection against the Omicron variant, researchers reported yesterday in The Lancet Infectious Diseases.
The authors say the finding of the study, the first to estimate the durability of protection conferred by hybrid immunity—the antibody response developed through a combination of SARS-CoV-2 infection and vaccination—could provide guidance on vaccine timing at both the individual and public health level.
Hybrid immunity highly protective against severe outcomes
Of the 26 studies reviewed by a team led by researchers from the University of Toronto and the World Health Organization, 11 reported on the protective effectiveness of previous infection, and 15 reported on protection from hybrid immunity; 7 reported on both. The studies looked at protection against reinfection, hospitalization, and severe disease caused by Omicron.
The effectiveness of previous infection against hospital admission or severe disease at 12 months was 74.6% (95% confidence interval [CI], 63.1% to 85.3%], with effectiveness against reinfection waning to 24.7% (95% CI, 16.4% to 35.5%) at 12 months. For hybrid immunity, protection against hospital admission or severe disease was 97.4% (95% CI, 91.4% to 99.2%) at 12 months with primary series vaccination and 95.3% (95% CI, 81.9% to 98.9%) at 6 months with the first booster shot. The effectiveness of hybrid immunity against reinfection waned to 41.8% (95% CI, 31.5% to 52.8%) at 12 months, and to 46.5% (95% CI, 36.0% to 57.3%) following the first booster shot at 6 months.
Further analysis of the 7 studies that reported on both types of protection showed that hybrid immunity conferred a significant gain in protection compared with previous infection alone—whether subjects with hybrid immunity had received the partial primary vaccine series, the full vaccine series, or the first booster shot.
The authors say the findings indicate that the protection conferred by previous infection should not detract from the need for vaccination, because infection-induced immunity wanes rapidly and vaccines increase the durability of protection. In addition, they suggest the results can be used to tailor guidance on the number and timing of SARS-CoV-2 vaccinations.
'Substantial durability' of hybrid immunity
"Our findings make clear the substantial durability of hybrid immunity and could help inform the timing and prioritisation of vaccination programmes in populations with high rates of past infection," the study authors wrote. "Policy makers can use these findings to project population protection from local vaccination and seroprevalence rates, helping to inform the use and timing of COVID-19 vaccination as an important public health tool."
They add that further analysis is needed to determine effectiveness of hybrid immunity against hospitalization or severe disease over a longer duration.
"A first-generation vaccine is still an excellent option when offered as a primary series in areas with a high rate of previous infection."
In an accompanying commentary, researchers with Brazil's Universidad Federal de Bahia say the findings demonstrate that the focus of first-generation vaccines should be prevention of severe disease.
"For this purpose, a first-generation vaccine is still an excellent option when offered as a primary series in areas with a high rate of previous infection, or with boosters, if a low infection rate has been observed," they wrote.
"For this purpose, a first-generation vaccine is still an excellent option when offered as a primary series in areas with a high rate of previous infection, or with boosters, if a low infection rate has been observed," they wrote.
More Good Stuff From CIDRAP:
- First-wave COVID patients had much higher risk of death for 18 months
- More than 65 million people around the world may have long COVID
- Feds probe possible stroke link to new Pfizer COVID booster
- Spanish hospitals spent $1.33 billion on COVID patients in 2020
- Convalescent plasma may cut risk of death in immune-impaired COVID patients
- Almost a fourth of air passengers screened from China had COVID-19, report reveals
- Paying people to take COVID vaccine worked well, study finds
No comments:
Post a Comment